A 24-Week, Multicenter, Randomized, Open-Label, 2-Arm Parallel-group Study Evaluating the Efficacy and Safety of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TAKE-CONTROL
- Sponsors Sanofi
- 14 Sep 2017 According to a Sanofi media release, full results from the study will be presented in 2018.
- 14 Sep 2017 Results published in a Sanofi media release.
- 27 Jun 2017 This trial has been completed in Denmark.